<DOC>
	<DOCNO>NCT01459198</DOCNO>
	<brief_summary>Human respiratory syncytial virus ( RSV ) common cause upper respiratory tract illnesses well severe low respiratory illness , include bronchiolitis pneumonia . RSV affect almost child within first 2 year life . This study evaluate safety immune response RSV MEDI ΔM2-2 vaccine among adult , RSV-seropositive child , RSV-seronegative infant child .</brief_summary>
	<brief_title>Evaluating Safety Immune Response Respiratory Syncytial Virus ( RSV ) Vaccine Adults , RSV-Seropositive Children , RSV-Seronegative Infants Children</brief_title>
	<detailed_description>The purpose study evaluate safety immune response RSV MEDI ΔM2-2 vaccine four group participant . The study vaccine evaluate adult , RSV-seropositive child , dose-ranging study two group RSV-seronegative infant child .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Adults : Adult male nonpregnant , nonnursing female 18 49 year old In good health without significant medical illness , physical examination finding , significant laboratory abnormality urinalysis , complete blood count ( CBC ) , alanine aminotransferase ( ALT ) , creatinine , determine study physician , physician assistant , nurse practitioner Available duration study Willing participate study evidence sign informed consent document Female participant childbearing potential must negative urine pregnancy test must agree use effective birth control method ( e.g. , birth control pill , diaphragm foam , condom spermicide , DepoProvera ) 28 day vaccination Exclusion Criteria Adults : Pregnant , determine positive urine human chorionic gonadotropin ( betaHCG ) test Breastfeeding Females childbearing potential unwilling practice effective birth control Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study , include urinalysis Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability person understand cooperate study protocol Other condition , opinion investigator , would jeopardize safety right participant study would render person unable comply protocol Has medical , occupational , family problem result alcohol illicit drug use 12 month prior study entry History severe allergic reaction anaphylaxis History splenectomy Current diagnosis asthma within 2 year prior study entry Positive enzymelinked immunosorbent assay ( ELISA ) confirmatory Western blot test HIV1 Positive ELISA confirmatory immunoblot test hepatitis C virus ( HCV ) Positive ELISA hepatitis B surface antigen ( HBsAg ) Abnormal urinalysis/urine dip Known immunodeficiency syndrome Receipt blood product ( include immunoglobulin ) within 3 month prior study entry Current smoker unwilling stop smoking duration study Previous enrollment RSV vaccine study Known hypersensitivity vaccine component Has professional and/or personal responsibility involve care child young 59 month age immunosuppressed individual Systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg Body mass index ( BMI ) great 35 Inclusion Criteria Seropositive Children : Healthy child 12 59 month age , whose parent/guardian understand sign study inform consent agrees vaccine administration follow detailed explanation study Seropositive RSV , define serum RSV neutralize antibody titer great 1:40 Person 's history review undergone physical examination indicate s/he good health Available duration study Exclusion Criteria Seropositive Children : Known suspected impairment immunological function , include maternal history positive HIV test , receive immunosuppressive therapy include systemic corticosteroid bone marrow/solid organ transplant recipient ( topical steroid , topical antibiotic , topical antifungal medication acceptable ) Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization RSV vaccine Previous serious vaccineassociated adverse event ( AE ) anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include wheeze event reactive airway disease . People clinically insignificant cardiac abnormality require treatment may enrol . People one episode wheeze receive bronchodilator therapy single episode illness first year life additional wheezing episode bronchodilator therapy least 12 month may also enrol . Member household include immunocompromised individual infant young 6 month age , study participant Attends day care infant younger 6 month age , whose parent/guardian unable unwilling suspend daycare 14 day follow immunization . Note : child attend facility separate child age minimize opportunity transmission virus direct physical aerosol contact acceptable . Inclusion Criteria Seronegative Infants Children : Healthy child 6 24 month age whose parents/guardians understand sign inform consent agree vaccine administration follow detailed explanation study Seronegative RSV antibody , define serum RSV neutralize antibody titer le 1:40 determine within 30 day prior inoculation Person 's history review undergone physical examination indicate s/he good health Available duration study Exclusion Criteria Seronegative Infants Children : Known suspected impairment immunological function , include maternal history positive HIV test , receive immunosuppressive therapy include systemic corticosteroid bone marrow/solid organ transplant recipient ( topical steroid , topical antibiotic , topical antifungal medication acceptable ) Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization RSV vaccine Previous serious vaccineassociated AE anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include wheeze event reactive airway disease . People clinically insignificant cardiac abnormality require treatment may enrol . People one episode wheeze receive bronchodilator therapy single episode illness first year life additional wheezing episode bronchodilator therapy least 12 month may also enrol . Member household include immunocompromised individual infant young 6 month age , study participant Attends day care infant less 6 month age , whose parent/guardian unable unwilling suspend daycare 14 day follow immunization . Children attend facility separate child age minimize opportunity transmission virus direct physical aerosol contact acceptable . Temporary Exclusion Criteria All Participants : The follow temporary selflimiting condition , resolve , person may enrol , otherwise eligible . If period temporary exclusion 56 day adults 30 day RSVseronegative child , person need rescreened . If period temporary exclusion 56 day RSVseropositive child , preinoculation serum antibody need collect . Fever ( adult oral temperature great equal 100.4°F [ 38°C ] pediatric rectal temperature great equal 100.4°F [ 38°C ] ) , upper respiratory illness ( rhinorrhea , cough , pharyngitis ) , nasal congestion significant enough interfere successful vaccination , otitis medium Has receive kill vaccine live attenuate rotavirus vaccine within 2 week prior study entry , live vaccine within 4 week prior study entry , gamma globulin ( antibody product ) within 3 month prior study entry Has receive another investigational vaccine investigational drug within 28 day receive investigational RSV vaccine Has receive antibiotic systemic nasal steroid therapy acute illness within 3 day prior vaccination ( steroid skin cream lotion topical antibiotic antifungal preparation permit ) Infant child participant receive salicylate ( aspirin ) salicylatecontaining product within 1 month prior study entry Infants bear less 37 week gestation le 1 year age</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>